309 results
8-K
EX-99.1
INSM
Insmed Incorporated
8 Aug 24
Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update
7:00am
Insmed reported positive topline safety and tolerability data as well as certain exploratory efficacy endpoints from the Phase 2 study … not been approved for any indication in any jurisdiction.
IMPORTANT SAFETY INFORMATION AND BOXED WARNING FOR ARIKAYCE IN THE U.S.
WARNING: RISK
8-K
INSM
Insmed Incorporated
3 Jul 24
Regulation FD Disclosure
9:00am
Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. A copy of the press
8-K
EX-99.2
INSM
Insmed Incorporated
3 Jul 24
Regulation FD Disclosure
9:00am
Exhibit 99.2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib … for brensocatib or acceptable prices for brensocatib; development of unexpected safety or efficacy concerns related to brensocatib; failure to obtain
8-K
EX-99.1
m1b0iby0m81
3 Jul 24
Regulation FD Disclosure
9:00am
8-K
EX-99.1
12d9ldo n0v5wba
4 Jun 24
Regulation FD Disclosure
7:00am
8-K
EX-99.2
dwb 2ncm1cojp8nv
30 May 24
Insmed Announces Proposed $500 Million Public Offering of Common Stock
5:32pm
8-K
EX-99.2
880m3 tl95y
30 May 24
Insmed Announces Proposed $500 Million Public Offering of Common Stock
5:32pm
8-K
EX-1.1
gcqnlvn7hf
30 May 24
Insmed Announces Proposed $500 Million Public Offering of Common Stock
5:32pm
424B5
1tpyp0ab3xwri
30 May 24
Prospectus supplement for primary offering
4:02pm
424B5
8jiqfgo75gc5y6
28 May 24
Prospectus supplement for primary offering
7:14pm
8-K
EX-99.2
b99 40jbrq
28 May 24
Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
6:30am
8-K
bxil2 hbrhxgiv4lbeh
28 May 24
Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
6:30am
8-K
EX-99.1
4ohnfuvnygr 8h
28 May 24
Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
6:30am
8-K
h4gx0
9 May 24
Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
7:05am
8-K
EX-99.1
9m42o9cxbbdlw
9 May 24
Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
7:05am
8-K
EX-99.2
bxmogna34st807
9 May 24
Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
7:05am